Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CFO Ryan D. Maynard sold 100,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $3.90, for a total value of $390,000.00. Following the completion of the sale, the chief financial officer now directly owns 100,000 shares of the company’s stock, valued at $390,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Rigel Pharmaceuticals, Inc. (RIGL) opened at $3.84 on Wednesday.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. Rigel Pharmaceuticals had a negative return on equity of 105.86% and a negative net margin of 354.14%. The company had revenue of $0.90 million during the quarter. During the same quarter in the prior year, the business earned ($0.24) earnings per share. The firm’s revenue was down 76.1% on a year-over-year basis. equities analysts expect that Rigel Pharmaceuticals, Inc. will post -0.6 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/08/ryan-d-maynard-sells-100000-shares-of-rigel-pharmaceuticals-inc-rigl-stock.html.

A number of institutional investors have recently bought and sold shares of RIGL. Parametric Portfolio Associates LLC lifted its position in shares of Rigel Pharmaceuticals by 11.3% during the first quarter. Parametric Portfolio Associates LLC now owns 30,815 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 3,118 shares in the last quarter. AXA bought a new stake in Rigel Pharmaceuticals during the 2nd quarter valued at $122,000. Voya Investment Management LLC grew its stake in shares of Rigel Pharmaceuticals by 30.4% in the 2nd quarter. Voya Investment Management LLC now owns 53,661 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 12,500 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Rigel Pharmaceuticals by 415.2% during the third quarter. SG Americas Securities LLC now owns 59,401 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 47,872 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Rigel Pharmaceuticals during the second quarter valued at about $193,000. Hedge funds and other institutional investors own 76.29% of the company’s stock.

A number of equities research analysts recently weighed in on the company. ValuEngine upgraded Rigel Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $5.00 target price on shares of Rigel Pharmaceuticals in a research note on Wednesday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Rigel Pharmaceuticals in a research note on Monday. Zacks Investment Research raised shares of Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, BMO Capital Markets restated a “buy” rating and set a $5.00 price target on shares of Rigel Pharmaceuticals in a research report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $5.67.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Receive News & Stock Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.